GSK has had another setback in its oncology ... an advisory committee meeting for renal anaemia drug daprodustat that recommended narrower use than hoped for, and the end of a partnership with ...

The decision makes Evrenzo (roxadustat) the first oral HIF-PH inhibitor to be cleared for use in the EU, ahead of rival candidates daprodustat from GlaxoSmithKline and Akebia Therapeutics' vadadustat.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...

As of November 08, 2024, GSK plc had a $73.1 billion market capitalization, putting it in the 96th percentile of companies in the Pharmaceuticals industry. Currently, GSK plc’s price-earnings ratio is ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Aditya Birla SL ELSS Tax Saver Fund (IDCW) 262.21 9,53,316 1.53 Aditya Birla SL ELSS Tax Saver Fund (G) 262.21 9,53,316 1.53 Aditya Birla SL ELSS Tax Saver Fund ...